Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

41.73 0.12 −0.29%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100

Teva Pharmaceutical Industries Ltd. (TEVA) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a EV/FCF of 46.2×. Over the past ten years it has ranged from 8.2× (April 2018) to 344× (April 2021); the current reading is higher than 72% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 41.4× (16.72%)
FY2024 49.8× 58.62%
FY2023 31.4× 20.12%
FY2022 26.1× (53.02%)
FY2021 55.6× 14.24%
FY2020 48.7× (22.68%)
FY2019 62.9× 294.13%
FY2018 16.0× 64.91%
FY2017 9.7× (13.24%)
FY2016 11.2× (0.05%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 44.3× 18.38%
Jun 2026 37.4× (3.47%)
Mar 2026 38.8× (6.49%)
Dec 2025 41.4× (32.39%)
43 more quarters

Against its own ten years

Low 8.2× High 344×
Ten-year median 33.3×
Current reading's percentile 69

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on TEVA